Optimal Testosterone Control and Eligard®

By: Bertrand Tombala lowast and Richard Bergesb

European Urology Supplements, Volume 6 Issue 12, July 2007, Pages 754-760

Published online: 01 July 2007

Keywords: Eligard, Hormone therapy, Leuprolide, Luteinising hormone-releasing hormone agonist, Prostate cancer, Testosterone

Abstract Full Text Full Text PDF (474 KB)



This review paper discusses the importance of optimal testosterone control in prostate cancer (PCa) and the advantages of the luteinising hormone-releasing hormone (LHRH) agonist Eligard® in this respect.


During an expert meeting in Marbella, Spain, in October 2006, PCa experts discussed optimal testosterone control and the role of Eligard. An interactive voting on these topics was held among the delegates. This paper reports on this meeting.


LHRH agonists should suppress testosterone levels to an extent equivalent to surgical castration. A significant proportion of patients on conventional LHRH agonists do not achieve surgical castration levels. In addition, a significant percentage of patients experience hormonal escape during treatment. Eligard uses a modern delivery system and offers 1-, 3- and 6-mo depot formulations. The Eligard 1-mo, 3-mo, and 6-mo formulations achieve testosterone levels ≤20ng/dl in up to 98% of patients. Injection-related and breakthrough testosterone escapes seldom occur. Eligard 6-mo formulation (45mg; Eligard 6) is the first LHRH agonist able to extend treatment for 6 mo. Eligard 6 allows flexible monitoring of patients because the need for visits solely to administer injections is removed. In addition, reducing the number of injections may help reduce psychological burden in patients who then are less often reminded of their condition.


Eligard provides optimal testosterone control in PCa patients, that is, achieves castration testosterone levels and is associated with a very low percentage of hormonal escapes. Eligard 6 offers flexibility in follow-up of patients and may help reduce emotional distress.

Take Home Message

The LHRH agonist Eligard provides optimal control of testosterone, that is, achieves and maintains testosterone levels equal to those obtained with orchidectomy. The 6-mo formulation offers flexible monitoring of the patient and may reduce emotional distress.

Keywords: Eligard, Hormone therapy, Leuprolide, Luteinising hormone-releasing hormone agonist, Prostate cancer, Testosterone.


a Cliniques Universitaires Saint-Luc, UCL, Brussels, Belgium

b PAN-Klinik am Neumarkt, Cologne, Germany

lowast Corresponding author. Cliniques Universitaires Saint-Luc UCL, Avenue Hippocrate 10, 1200 Brussels, Belgium. Tel. +32 2 764 550 40; Fax: +32 2 764 55 80.

Place a comment

Your comment *

max length: 5000